STRO Sutro Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: STRO

Price (delayed)

$28.53

Market cap

$472.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$16.43

Enterprise value

$411.85M

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 35

Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Highlights
The quick ratio has soared by 56% from the previous quarter and by 54% YoY
STRO's EPS is up by 44% YoY and by 27% from the previous quarter
The equity has dropped by 159% year-on-year but it is up by 50% since the previous quarter
The gross profit has grown by 50% YoY but it has contracted by 2.8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sutrobio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of STRO

STRO stock price

How has the Sutro Biopharma stock price performed over time
Intraday
4.97%
1 week
-3.71%
1 month
-25.68%
1 year
213.86%
YTD
146.59%
QTD
14.53%

Financial performance

How have Sutro Biopharma's revenue and profit performed over time
Revenue
$99.61M
Gross profit
$99.61M
Operating income
-$119.51M
Net income
-$153.6M
Gross margin
100%
Net margin
-154.2%
STRO's operating margin has soared by 68% YoY and by 22% QoQ
The company's net margin has surged by 58% YoY and by 17% QoQ
STRO's operating income has surged by 52% year-on-year and by 25% since the previous quarter
The gross profit has grown by 50% YoY but it has contracted by 2.8% from the previous quarter

Price vs fundamentals

How does STRO's price correlate with its fundamentals

Growth

What is Sutro Biopharma's growth rate over time

Valuation

What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
3.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.13
STRO's EPS is up by 44% YoY and by 27% from the previous quarter
The equity has dropped by 159% year-on-year but it is up by 50% since the previous quarter
The stock's price to sales (P/S) is 155% more than its last 4 quarters average of 1.4 but 19% less than its 5-year quarterly average of 4.4
Sutro Biopharma's revenue has increased by 50% YoY but it has decreased by 2.8% QoQ

Efficiency

How efficient is Sutro Biopharma business performance
STRO's ROS has soared by 53% YoY and by 19% from the previous quarter
STRO's return on invested capital is up by 23% since the previous quarter but it is down by 15% year-on-year
STRO's return on assets is down by 16% year-on-year but it is up by 12% since the previous quarter

Dividends

What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STRO.

Financial health

How did Sutro Biopharma financials performed over time
STRO's total assets is 22% smaller than its total liabilities
The quick ratio has soared by 56% from the previous quarter and by 54% YoY
Sutro Biopharma's current ratio has soared by 55% from the previous quarter and by 44% YoY
The company's debt is 120% higher than its equity
The equity has dropped by 159% year-on-year but it is up by 50% since the previous quarter
Sutro Biopharma's debt to equity has soared by 76% YoY but it has plunged by 67% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.